SOURCE: Xtalks

Xtalks Webinars

May 05, 2017 07:30 ET

Expanding the Potential of Immuno-Oncology Therapies, a New Webinar Presented by Premier Research and Hosted by Xtalks

TORONTO, ON--(Marketwired - May 05, 2017) - In an informative session on Tuesday, May 23, 2017 at 11:00am EST (4pm BST/UK), industry experts Nina Baluja, Senior Medical Director of Medical Services and Luke Gill, Executive Director of Oncology, Strategic Development, both from Premier Research, will discuss the promising approaches in immuno-oncology drug development including checkpoint inhibitors, antibody drug conjugates, autologous cellular immunotherapy, and oncolytic viruses. This webinar will explore each of these, along with challenges in researching these compounds and recommendations to improve your odds of success.

Immuno-modulating agents such as interleukin-2 and interferon have been used to treat some solid malignancies for years, but their use has generally been limited to cancers considered immunogenic - for example, melanoma and kidney cancers. Today, multiple immuno-oncology pathways are in development.

For instance, checkpoint inhibitors include monoclonal antibodies that target the cytotoxic T-lymphocyte associated antigen 4 (CTLA-4). Examples are ipilimumab - marketed as Yervoy - a drug that binds to the CTLA-4 on T cells and is indicated for treatment of unresectable metastatic melanoma, and programmed-death drugs such as pembrolizumab (Keytruda) that activate the immune system to attack tumors.

Clinical Trial Challenges

Response and efficacy of oncology agents is measured by RECIST (Response Evaluation Criteria in Solid Tumors), a set of published rules that define when cancer patients improve, stay the same, or worsen. This webinar will discuss why these criteria do not easily apply in immuno-oncology and how these realities gave rise to the immune-related response criteria - published rules that define when tumors respond, stabilize, or worsen.

Trial Planning Success Tips

Effective site training is essential when planning trials of immuno-oncology agents. In addition, combination studies should be planned early. This webinar will reveal how sufficient planning can reveal if a combination with a chemotherapy or other agent provides better efficacy without increasing toxicity.

For details or to register for this complimentary event visit:

About Premier Research

Premier Research is a leading contract research organization serving the needs of biotechnology, pharmaceutical, and medical device companies worldwide. The company has a wealth of experience in the execution of global, regional, and local clinical development programs, with a special focus on addressing unmet needs in areas such as analgesia, CNS, rare diseases, medical device and diagnostics, oncology, and pediatric research. Premier Research operates in 84 countries and employs more than 1,000 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. With its mission to improve productivity in clinical development, the company aligns itself with the mission of its customers to bring new medical treatments to patients promptly, accurately, and cost-effectively.

To learn more about Premier Research visit:

About Xtalks

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit

For information about hosting a webinar visit

Image Available:

Contact Information